Hi guys, I'm currently a pharmacy student going into my 4th year. I read a few threads on this forum about biotech investing, and it really caught my attention. I am really interested to learn more about it, how it works, how to predict stock, where to get FDA release information, etc. Does anyone have any advice, or any books that I can read to learn more about Biotech Investing, I really appreciate it. Thank You.
Need help with Biotech Investing
- Thread starter STAR3URY
- Start date
B
BelleMD2B
Wow...
Um, this is NOT the place to solicit advice about biotech investing. That is the advice I will give. Not to mention one man's success story is another man's road to bankruptcy.
Um, this is NOT the place to solicit advice about biotech investing. That is the advice I will give. Not to mention one man's success story is another man's road to bankruptcy.
Well I'm not asking anyone to tell me what exactly to invest in. I am just a novice and I want to learn, so I wanted to see if there are any helpful websites, or books that I can read just to get my foot in there and see how things work.
- Joined
- Dec 19, 2004
- Messages
- 10,410
- Reaction score
- 4,038
Z said to look at positive stage III trial results.
Is there like a database that lists all the ongoing phase III trials or something?
- Joined
- Jun 20, 2009
- Messages
- 61
- Reaction score
- 0
Before you narrow your investing to biotech, you should probably learn the fundamentals of investing. A general primer for basic fundamental analysis is Benjamin Grahams, The Intelligent Investor. Old book but generally the stepping stone for getting into the stock market.
- Joined
- May 11, 2005
- Messages
- 339
- Reaction score
- 0
Just find (or find the lack of) unperceived value.
Most pharmacists are actually pretty good at telling if a drug is BS, sales are getting eroded by new competition, likely to get taken off the market, or the marketplace is overhyping things. I'd even wager that analysts don't sufficiently include patent expiry very well (Who in this world would buy Pfizer??? What will they sell with no more Lipitor and Viagra?)
Personal story:
When the whole H1N1 thing was coming out, I was doing a practical placement at a hospital, and receiving the public health emails about suspicious cases involving young otherwise healthy people returning to Mexico. In other words, I had info that was public, but realistically, financial people didn't pay any attention to, and mind as well have been "inside" info. And the whole thing just kept growing and growing.
So I looked up the neuraminidase inhibitors that are available, zanamavir, oseltamavir, and a novel injectable undergoing Phase II (or was it III?) trials, peramivir.
This was in mid-late March 2009 I believe, and the stock was around $1.50.
Since I was toward the very end of my schooling, I was penny-less. Most of us are never poorer at any part of their careers than they are at this point.
I guess I could've made a good chunk of change, no?
http://www.google.com/finance?chdnp...4&chls=IntervalBasedLine&q=NASDAQ:BCRX&ntsp=0
Secondly, pharmacists typically have more stable incomes than others, so they should be playing the "buy low, sell high" game better than most. I think I'm going to load on some JNJ soon, I think I can "stomach" a P/E of 12
Most pharmacists are actually pretty good at telling if a drug is BS, sales are getting eroded by new competition, likely to get taken off the market, or the marketplace is overhyping things. I'd even wager that analysts don't sufficiently include patent expiry very well (Who in this world would buy Pfizer??? What will they sell with no more Lipitor and Viagra?)
Personal story:
When the whole H1N1 thing was coming out, I was doing a practical placement at a hospital, and receiving the public health emails about suspicious cases involving young otherwise healthy people returning to Mexico. In other words, I had info that was public, but realistically, financial people didn't pay any attention to, and mind as well have been "inside" info. And the whole thing just kept growing and growing.
So I looked up the neuraminidase inhibitors that are available, zanamavir, oseltamavir, and a novel injectable undergoing Phase II (or was it III?) trials, peramivir.
This was in mid-late March 2009 I believe, and the stock was around $1.50.
Since I was toward the very end of my schooling, I was penny-less. Most of us are never poorer at any part of their careers than they are at this point.
I guess I could've made a good chunk of change, no?
http://www.google.com/finance?chdnp...4&chls=IntervalBasedLine&q=NASDAQ:BCRX&ntsp=0
Secondly, pharmacists typically have more stable incomes than others, so they should be playing the "buy low, sell high" game better than most. I think I'm going to load on some JNJ soon, I think I can "stomach" a P/E of 12
- Joined
- Apr 2, 2008
- Messages
- 4,191
- Reaction score
- 2,522
Looking back March 2009, anyone who is into stock market know if you pick 10 random stocks, 8 of them would rally 50-400%+... that just points how you know about picking a good biotech stock or anything about investing at all...
- Joined
- May 11, 2005
- Messages
- 339
- Reaction score
- 0
Certainly a fundamental issue with investing is whether to attribute success to good "picking" or luck.Looking back March 2009, anyone who is into stock market know if you pick 10 random stocks, 8 of them would rally 50-400%+... that just points how you know about picking a good biotech stock or anything about investing at all...
What you said was true about big finance or industrial stocks, but not so much biotech stocks, especially small-caps, where their value fluctuates with their successes/failures in their patents+trials+marketplace rather than the market at large. The other 400%+ gainers in the market were ugly finance firms that got bailed-out instead of taken to pasture, in other words, they went from having nearly no value, to some value.
http://www.google.com/finance?chdnp...E&cmptdms=0;0;0;0;0;0;0;0;0&q=NYSE:PFE&ntsp=0
I've compared this stock to the regular pharma companies, and GE as another finance/industrial hybrid. I think it proves that a 50% movement in the broad market doesn't mean much when looking at this explosion.
